A securities class action lawsuit filed against ARS Pharmaceuticals, Inc. names Chief Commercial Officer Eric Karas as an individual defendant, alleging that executives misled investors regarding the timeline and progress of expanded commercial coverage for the needle-free nasal spray neffy. According to a notice issued by Levi & Korsinsky, LLP, the complaint covers purchasers of ARS Pharmaceuticals securities between March 9, 2026, and June 24, 2026, and establishes a lead plaintiff deadline of October 5, 2026.
Share Price Decline Follows Delayed CVS Caremark Formulary Decisions
The litigation centers on a sharp drop in ARS Pharmaceuticals stock following an announcement that anticipated formulary expansions had failed to materialize for the summer and back-to-school cycles. According to Levi & Korsinsky, LLP, SPRY shares closed at $10.54 on June 24, 2026, before falling to $8.02 in the subsequent trading session. That single-session decline of $2.52 per share wiped out roughly 23.9% of the stock’s value across approximately 99.3 million shares outstanding.
After the market closed on June 24, 2026, the company disclosed that no new commercial formulary additions or coverage decisions had been issued for neffy in the July 1, 2026 cycle. The disclosure meant that expanded CVS Caremark coverage would not take effect as some investors had anticipated, removing a primary catalyst that market participants had tracked for revenue growth.
Executive Statements and Market Access Strategy Under Scrutiny
The class action complaint alleges that individual corporate officers, including the company’s then-Chief Executive Officer and Chief Commercial Officer Eric Karas, made public statements that failed to disclose the risk of delays in securing major payer contracts. As Chief Commercial Officer, Karas managed market access and payer strategy for neffy and served as a featured speaker on quarterly earnings calls.
During an earnings call on March 9, 2026, Karas reported that the company maintained approximately 93% overall commercial coverage, with roughly 57% of covered lives accessing neffy without prior authorization. He highlighted a high level of focus on CVS Caremark, Anthem, and large regional payers to secure unrestricted commercial access. Later, on a May 15, 2026 earnings call, Karas stated that the CVS Caremark proposal was in the final stages of the approval process and that the broader payer process was nearing completion.
The lawsuit contends these characterizations painted an overly optimistic picture of the July 1 formulary timeline while omitting the risk that negotiations could stall or push decisions into January 2027. Plaintiffs argue that investors purchased shares at artificially inflated prices based on these representations before the company revealed the absence of new additions for the summer cycle.
Legal Representation and Investor Deadlines
Investors who suffered financial losses on ARS Pharmaceuticals securities during the designated class period may contact Joseph E. Levi, Esq. at Levi & Korsinsky, LLP to discuss potential recovery options. The firm notes that affected shareholders have until October 5, 2026, to file motions seeking appointment as lead plaintiff in the action.
The complaint asserts violations under Section 10(b) and Section 20(a) of the Securities Exchange Act of 1934.